Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Future therapies for cystic fibrosis
Lucy Allen, Lorna Allen, S.B. Carr, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 27
Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians
Vito Terlizzi, Philip M. Farrell
Current problems in pediatric and adolescent health care (2024) Vol. 54, Iss. 6, pp. 101637-101637
Closed Access | Times Cited: 24
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Guobo Shen, Jian Liu, Hanmei Yang, et al.
Journal of Controlled Release (2024) Vol. 369, pp. 696-721
Closed Access | Times Cited: 19
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
Claire Keating, Lael M. Yonker, F. Vermeulen, et al.
The Lancet Respiratory Medicine (2025)
Open Access | Times Cited: 10
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Nicole Mayer-Hamblett, John P. Clancy, Raksha Jain, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 10, pp. 932-944
Open Access | Times Cited: 23
Chloride channels and mast cell function: pioneering new frontiers in IBD therapy
Ahmed M. Aljameeli, Bader Alsuwayt, Deepak Bharati, et al.
Molecular and Cellular Biochemistry (2025)
Closed Access | Times Cited: 1
Active microgel particle swarms for intrabronchial targeted delivery
Hui Chen, Junhui Law, Yibin Wang, et al.
Science Advances (2025) Vol. 11, Iss. 11
Closed Access | Times Cited: 1
CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes
Juliet Lefferts, Marlou C. Bierlaagh, Suzanne Kroes, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14539-14539
Open Access | Times Cited: 21
Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions
Belal Tafech, Mohammad‐Reza Rokhforouz, Jerry Leung, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 18
Open Access | Times Cited: 8
A review of HSV pathogenesis, vaccine development, and advanced applications
Lan Bai, Jiuzhi Xu, Linghui Zeng, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 8
Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives
Vijay Kumar Panthi, Kathryn E. Fairfull‐Smith, Nazrul Islam
Journal of Drug Delivery Science and Technology (2024) Vol. 94, pp. 105517-105517
Open Access | Times Cited: 6
Considerations for the use of inhaled antibiotics forPseudomonas aeruginosain people with cystic fibrosis receiving CFTR modulator therapy
Pierre–Régis Burgel, Manfred Ballmann, Pavel Dřevı́nek, et al.
BMJ Open Respiratory Research (2024) Vol. 11, Iss. 1, pp. e002049-e002049
Open Access | Times Cited: 6
Arteriovenous metabolomics in pigs reveals CFTR regulation of metabolism in multiple organs
Hosung Bae, Bo Ram Kim, Sunhee Jung, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 13
Open Access | Times Cited: 6
On the path to predicting immune responses in the lung: Modeling the pulmonary innate immune system at the air-liquid interface (ALI)
Jodi Graf, Michael Trautmann-Rodriguez, Simone Sabnis, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 191, pp. 106596-106596
Open Access | Times Cited: 10
Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study
Annelies M. Zwitserloot, Shima Aziz, Yuxin Chen, et al.
Pediatric Pulmonology (2025) Vol. 60, Iss. 1
Open Access
Short-term modification of breathprint by Elexacaftor/Tezacaftor/Ivacaftor in a paediatric cohort
Emmanuelle Bardin, N. Hunzinger, Elodie Lamy, et al.
Journal of Cystic Fibrosis (2025)
Open Access
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis
Xueqing Wang, Chris Tse, Ashvani K. Singh
Journal of Medicinal Chemistry (2025)
Closed Access
Qualitative study exploring the views and perceptions of parents/carers of young children with CF regarding the introduction of CFTR modulator therapy (The REVEAL study; PaRents pErspectiVEs of KAftrio in chiLdren aged 2–5)
Sioned Davies, Francis Wade, Heather Fogg, et al.
BMJ Open Respiratory Research (2025) Vol. 12, Iss. 1, pp. e002522-e002522
Open Access
Identifying novel therapeutic targets in cystic fibrosis through advanced single-cell transcriptomics analysis
George Sun, Yi‐Hui Zhou
Computers in Biology and Medicine (2025) Vol. 187, pp. 109748-109748
Open Access
Unraveling the Mechanism of Action, Binding Sites, and Therapeutic Advances of CFTR Modulators: A Narrative Review
Debora Baroni
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 2, pp. 119-119
Open Access
Evidence for altered immune-structural cell crosstalk in cystic fibrosis revealed by single cell transcriptomics
Marijn Berg, Lisette Krabbendam, Esmee K. van der Ploeg, et al.
Journal of Cystic Fibrosis (2025)
Open Access
Lipid-based nanocarriers in management of cystic fibrosis: A pulmonary complication
Shubhrat Maheshwari, Aditya Singh, Sudarshan Singh, et al.
Elsevier eBooks (2025), pp. 435-448
Closed Access
Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis
Burcu Uzunoğlu, Merve Selçuk, Mine Kalyoncu, et al.
Pediatric Pulmonology (2025) Vol. 60, Iss. 3
Open Access
Gene Therapy for Cystic Fibrosis: Overcoming Current Limitations and Future Directions
Nadir Ali Wassan, Asfia Qammar, Sarah Bürki, et al.
Indus journal of bioscience research. (2025) Vol. 3, Iss. 3, pp. 133-145
Closed Access
Race, genetic ancestry, and socioeconomic status – a tangled web
Michael S. Schechter
Journal of Cystic Fibrosis (2025)
Closed Access
Page 1 - Next Page

Scroll to top